Neutropenia Treatment Market By Drug Type (G-CSF, GM-CSF, Antibiotics, Antifungal, Antiviral), By Pipeline Analysis (Plinabulin - Phase 2/3, EC-18 - Phase 2, SPI-2012 - Phase 3, rHSA-GCSF 2.4mg - Phase 2, Probio-Fix Inum - Phase 2, Pegteograstim - Phase 2, F-627 - Phase 3, Astragalus polysaccharides 500 mg - Phase 2, Leucostim - Phase 3, myelo001 - Phase 3, Romyelocel-L - Phase 3) - Growth, Future Prospects and Competitive Analysis, 2019-2027

Neutropenia treatment accounted for a market value of US$ 11,279.2 Mn in 2018 and projected to grow at a CAGR of 5.0% during the forecast period from 2019 to 2027. In neutropenia count of neutrophil falls giving rise to compromised immunity further increasing the risk of infection. Neutropenia is observed in almost half cases of cancer patients being treated with chemotherapy but out of them most are suffering from leukaemia. According to medical experts, neutropenia can be a chronic condition because without adequate neutrophils patient become vulnerable to life-threatening infections.

"Strong drug pipeline will assist the significant growth of neutropenia treatment market throughout the forecast period"

Drug pieline of neutropenia treatment is equipped with several promising drugs in phase III of clinical trials such as SPI-2012 (Spectrum Pharmaceuticals, Inc.), F-627 (Generon (Shanghai) Corporation Ltd.), Leucostim (Dong-A ST Co., Ltd.), myelo001 (Myelo Therapeutics, Inc.), Plinabulin (BeyondSpring Pharmaceuticals Inc.), and Romyelocel-L (Cellerant Therapeutics, Inc.). Neutropenia caused due to several causes major being the post-chemotherapy decrease in count of neutrophils. Increasing prevalence of leukemia expected to rise the neutropenia cases as chemotherapy being the first-line of treatment for leukemia. However, precautionary treatment regimen is ready to avoid effect of neutropenia-based infections with antibacterial, antiviral and antifungal drugs.

"North America dominated the overall global market specifically due to promising drug pipeline, and developed diagnostic landscape"

In 2018, North America dominated the market and expected to retain its position throughout the forecast period due to rising awareness related to neutropenia, increasing prevalence of side effects related to chemotherapy during leukemia treatment, and high expectation from drugs in pipeline. According to several studies, the prevalence of neutropenia is around 4.4% and expected to increase in specific regions with rising prevalence of leukemia. During the forecast period from 2019 to 2027, Asia Pacific will grow gradually due to increasing awareness related to neutropenia diagnosis & treatment coupled with developing diagnostic technologies in rare disease sector.

Historical & Forecast Period

The neutropenia treatment market analyzed considering current market trends for base year 2018 and based on future trends CAGRs calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report comprises detailed qualitative and quantitative data related to the neutropenia treatment market along with key factors related to the market such as opportunities, drivers, & restraints. An elaborative data covering market drivers, challenges & opportunities provided explicitly for country-level and regional segmentation. This report covered brief information associated with the global neutropenia treatment market segmented such as drug class type, and geography. The pipeline analysis of neutropenia treatment market comprising drugs under trials in preclinical studies phase I, II & III. Competitive analysis of the major companies is included in neutropenia treatment market along with detailed data related to the competitive landscape of the market and recent strategies & products entering the market.

The key companies included in the neutropenia treatment industry analyzed based on financial data, product portfolio, current press releases, and major market strategies. This report also includes attractive investment proposition studied based on exclusive geographical PESTEL analysis. Major companies included in the report are Amgen, Inc., Spectrum Pharmaceuticals, Inc., Generon (Shanghai) Corporation Ltd., Dong-A ST Co., Ltd., BeyondSpring Pharmaceuticals Inc., Myelo Therapeutics, Inc., Cellerant Therapeutics, Inc., and Sandoz (Subsidiary of Novartis AG) among others.

Key questions answered in this report

• Which is the most frequent drug class to manage & treat neutropenia & Why?
• What are the novel market strategies followed by the major companies & competitive landscape of the neutropenia treatment market?
• Which are the recent and upcoming drugs in neutropenia treatment market?
• Which is the largest and fastest-growing neutropenia treatment segment globally?
• What are the drivers, restraints, & opportunities in the neutropenia treatment market?
• Which are the major geographical markets (regions and countries) of neutropenia treatment market?